InnoCare to Start China Trial of TYK2 Inhibitor for Autoimmune Diseases

Beijing 's InnoCare reported China approved a Phase I trial of its novel oral TYK2 (Tyrosine Kinase 2) inhibitor, the company’s fifth innovative drug to start clinical trials. ICP-332 is designed to be a potent and selective TYK2 inhibitor with a 400 fold improvement in selectivity against JAK2 to avoid the adverse events associated with non-selective JAK inhibitors. It will be tested as a therapy for autoimmune diseases such as psoriasis and atopic dermatitis. No selective TYK2 inhibitors are approved globally. More details.... Stock Symbol: (HK: 09969) Share this with colleagues: // //